sunvozertinib,amivantamab
janssen,dizal pharmaceuticals
['sunvozertinib', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'amivantamab']
sunvozertinib for the treatment of nsclc with egfr exon20 insertion mutations. dose 300 mg/d. promising 61% orr (n=97). responses included pts with brain mets, different point mutations, and previously treated with amivantamab #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm